Log in

NASDAQ:EYESSecond Sight Medical Products Stock Price, Forecast & News

+0.02 (+2.00 %)
(As of 06/3/2020 04:00 PM ET)
Today's Range
Now: $1.02
50-Day Range
MA: $1.26
52-Week Range
Now: $1.02
Volume1.20 million shs
Average Volume318,511 shs
Market Capitalization$15.97 million
P/E RatioN/A
Dividend YieldN/A
Second Sight Medical Products, Inc. develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. It also offers Argus II Retinal Prosthesis System for treating retinitis pigmentosa. The company was founded in 1998 and is headquartered in Sylmar, California.
Read More
Second Sight Medical Products logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.51 out of 5 stars

Industry, Sector and Symbol

Industry Electromedical equipment
Current SymbolNASDAQ:EYES



Sales & Book Value

Annual Sales$3.38 million
Book Value$0.47 per share


Net Income$-33,590,000.00
Net Margins-994.14%


Market Cap$15.97 million
Next Earnings DateN/A

Receive EYES News and Ratings via Email

Sign-up to receive the latest news and ratings for EYES and its competitors with MarketBeat's FREE daily newsletter.

Second Sight Medical Products (NASDAQ:EYES) Frequently Asked Questions

How has Second Sight Medical Products' stock been impacted by COVID-19 (Coronavirus)?

Second Sight Medical Products' stock was trading at $3.53 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, EYES shares have decreased by 71.1% and is now trading at $1.02. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Second Sight Medical Products?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Second Sight Medical Products in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Second Sight Medical Products.

How were Second Sight Medical Products' earnings last quarter?

Second Sight Medical Products Inc (NASDAQ:EYES) posted its quarterly earnings results on Thursday, March, 19th. The medical device company reported ($0.50) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.49) by $0.01. The medical device company earned $0.50 million during the quarter, compared to analysts' expectations of $0.83 million. Second Sight Medical Products had a negative net margin of 994.14% and a negative return on equity of 183.76%. View Second Sight Medical Products' earnings history.

What price target have analysts set for EYES?

2 Wall Street analysts have issued 12-month target prices for Second Sight Medical Products' stock. Their forecasts range from $2.00 to $2.50. On average, they expect Second Sight Medical Products' share price to reach $2.25 in the next year. This suggests a possible upside of 120.6% from the stock's current price. View analysts' price targets for Second Sight Medical Products.

Has Second Sight Medical Products been receiving favorable news coverage?

News headlines about EYES stock have been trending very negative on Thursday, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Second Sight Medical Products earned a media sentiment score of -3.0 on InfoTrie's scale. They also gave news articles about the medical device company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news aboutSecond Sight Medical Products.

Are investors shorting Second Sight Medical Products?

Second Sight Medical Products saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 774,600 shares, an increase of 9.0% from the April 30th total of 710,700 shares. Based on an average trading volume of 293,600 shares, the days-to-cover ratio is presently 2.6 days. Currently, 10.2% of the shares of the stock are sold short. View Second Sight Medical Products' Current Options Chain.

Who are some of Second Sight Medical Products' key competitors?

What other stocks do shareholders of Second Sight Medical Products own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Second Sight Medical Products investors own include Zynerba Pharmaceuticals (ZYNE), Adaptimmune Therapeutics (ADAP), Cara Therapeutics (CARA), Shopify (SHOP), Opko Health (OPK), Canopy Growth (CGC), VBI Vaccines (VBIV), Corbus Pharmaceuticals (CRBP), TransEnterix (TRXC) and Plug Power (PLUG).

Who are Second Sight Medical Products' key executives?

Second Sight Medical Products' management team includes the following people:
  • Mr. Jonathan Will McGuire, CEO, Pres & Director (Age 56)
  • Mr. John T. Blake, CFO & Corp. Sec. (Age 43)
  • Mr. William Patrick Ryan, Chief Operating Officer (Age 58)
  • Gunnar Bjorg, Founder
  • Mr. Stephen D. Okland Jr., Chief Commercial Officer (Age 55)

When did Second Sight Medical Products IPO?

(EYES) raised $32 million in an initial public offering on Wednesday, November 19th 2014. The company issued 3,500,000 shares at a price of $9.00 per share. MDB Capital Group, LLC acted as the underwriter for the IPO.

What is Second Sight Medical Products' stock symbol?

Second Sight Medical Products trades on the NASDAQ under the ticker symbol "EYES."

Who are Second Sight Medical Products' major shareholders?

Second Sight Medical Products' stock is owned by many different institutional and retail investors. Top institutional shareholders include Versant Venture Management LLC (3.59%) and BlackRock Inc. (0.25%). Company insiders that own Second Sight Medical Products stock include Edward David Randolph, Gregg Williams, Jonathan Will Mcguire and Stephen D Okland. View institutional ownership trends for Second Sight Medical Products.

Which institutional investors are selling Second Sight Medical Products stock?

EYES stock was sold by a variety of institutional investors in the last quarter, including Versant Venture Management LLC, and BlackRock Inc.. Company insiders that have sold Second Sight Medical Products company stock in the last year include Edward David Randolph, and Jonathan Will Mcguire. View insider buying and selling activity for Second Sight Medical Products.

How do I buy shares of Second Sight Medical Products?

Shares of EYES can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Second Sight Medical Products' stock price today?

One share of EYES stock can currently be purchased for approximately $1.02.

How big of a company is Second Sight Medical Products?

Second Sight Medical Products has a market capitalization of $15.97 million and generates $3.38 million in revenue each year. The medical device company earns $-33,590,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis. Second Sight Medical Products employs 123 workers across the globe.

What is Second Sight Medical Products' official website?

The official website for Second Sight Medical Products is www.secondsight.com.

How can I contact Second Sight Medical Products?

Second Sight Medical Products' mailing address is 12744 SAN FERNANDO ROAD SUITE 400, SYLMAR CA, 91342. The medical device company can be reached via phone at 818-833-5000 or via email at [email protected]

This page was last updated on 6/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.